Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
Polaryx Therapeutics confirmed it is on track to initiate the SOTERIA Phase 2 basket trial in the fourth quarter of 2026. The company has secured necessary FDA authorization, engaged a contract research organization, and received Fast Track Designation for PLX-200 across four indications including CLN2 and Krabbe disease.
Key figures
- Trial id
- NCT07740512
- Financing amount
- $10 million
- Interim analysis weeks
- 52
- Maintenance period weeks
- 96
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.